Startup Risk DNA Analysis
by Innovance Global Advisors
The Startup Risk DNA Analysis from Innovance Global Advisors enables users to identify fatal business patterns before they become terminal. By evaluating seven core "genetic markers"—including founder team dynamics, cash runway, market validation, competitive moat, business model clarity, execution readiness, and funding alignment—users receive an immediate diagnostic assessment of their startup's risk profile. Similar to genetic screening that identifies disease markers, this tool analyzes your business DNA against documented startup failure patterns to reveal critical vulnerabilities.
Note: The analysis is grounded in established research showing that 90% of startups fail for recurring, preventable reasons—building products nobody wants (42%), running out of cash (29%), wrong team composition (23%), being outcompeted (19%), and unclear business models (17%). Results are intended for diagnostic and informational purposes only and do not constitute business or financial advice.
Disclaimer: The results provided by this Startup Risk DNA Analysis are for diagnostic and informational purposes only and do not constitute business, legal, financial, or investment advice. This tool identifies common risk patterns associated with startup failures based on statistical research and industry benchmarks. The analysis relies on self-reported data and general risk indicators, which may not capture the full complexity of your startup's unique circumstances, market conditions, or potential opportunities. Risk assessment does not predict or guarantee business outcomes—both successful and failed startups can share similar markers. For a comprehensive risk mitigation strategy and personalized guidance, we strongly recommend scheduling a consultation with Innovance Global Advisors. Our advisors specialize in helping startups navigate the specific challenges of the Portuguese and international markets. Use of this tool is entirely at your own discretion and risk.